{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-035503","form_type":"8-K","ticker":"GCTK","cik":"0001506983","company_name":"Glucotrack, Inc.","filed_at":"2026-07-30T21:29:16+00:00","discovered_at":"2026-07-30T21:30:00.335068+00:00","generated_at":"2026-07-30T21:30:03.997678+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Glucotrack subsidiary Lokahi advances LT-100 to single-injection strategy after FDA meeting","bullets":["Lokahi Therapeutics (GCTK subsidiary) plans to simplify LT-100 from 15 intradermal injections to a single subcutaneous injection per visit.","Type C meeting with FDA in May 2026 supported the proposed clinical strategy for LT-100.","Nonclinical minipig study showed subcutaneous administration achieved systemic exposure consistent with prior intradermal data.","Clinical evaluation of single-injection approach expected to begin as early as Q4 2026, with initial readout in H1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-035503","json":"https://secwatch.observer/filing/0001493152-26-035503.json","markdown":"https://secwatch.observer/filing/0001493152-26-035503.md","text":"https://secwatch.observer/filing/0001493152-26-035503.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226035503/0001493152-26-035503-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226035503/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T21:30:03.997678+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}